Abstract
Background/Aims: Artificial ulcers remain a major complication after Endoscopic submucosal dissection (ESD). The development of more effective treatment regimen for this ulcer is required than the use of proton pump inhibitor (PPI) alone. Methodology: Patients with ESD-derived artificial ulcers were randomly assigned to two groups: a group of patients who received rabeprazole 20 mg daily for 8 weeks (PPI group) and a group of patients who received a combination of rebamipide 300 mg daily for 8 weeks and rabeprazole 20mg dairy for the first 4 weeks (reb+PPI group). The area reduction ratio and healing status of ulcers were evaluated endoscopically on postoperative 7, 28 and 56 days. Results: The overall ulcer area reduction ratio was higher in the reb+PPI group than in the PPI group, especially at an early stage. The ratio of progression to the H1 stage in the reb+PPI group was significantly higher than that in the PPI group, especially at an early stage. Conclusions: Treatment with 8 weeks of rebamipide plus the first 4 weeks of PPI demonstrated a reduction ratio of artificial ulcers superior to that with 8 weeks of PPI mono-therapy. This combination treatment is, therefore, one of the candidate treatment strategies against ESD-derived artificial ulcers.
| Original language | English |
|---|---|
| Pages (from-to) | 219-224 |
| Number of pages | 6 |
| Journal | Hepato-Gastroenterology |
| Volume | 62 |
| Issue number | 137 |
| DOIs | |
| Publication status | Published - 01-01-2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
- Gastroenterology
Cite this
}
The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer : A randomized controlled trial. / Nakamura, Masakatsu; Tahara, Tomomitsu; Shiroeda, Hisakazu; Matsunaga, Kazuhiro; Otsuka, Toshimi; Yonemura, Hoh; Shibata, Tomoyuki; Arisawa, Tomiyasu.
In: Hepato-Gastroenterology, Vol. 62, No. 137, 01.01.2015, p. 219-224.Research output: Contribution to journal › Article
TY - JOUR
T1 - The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer
T2 - A randomized controlled trial
AU - Nakamura, Masakatsu
AU - Tahara, Tomomitsu
AU - Shiroeda, Hisakazu
AU - Matsunaga, Kazuhiro
AU - Otsuka, Toshimi
AU - Yonemura, Hoh
AU - Shibata, Tomoyuki
AU - Arisawa, Tomiyasu
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Background/Aims: Artificial ulcers remain a major complication after Endoscopic submucosal dissection (ESD). The development of more effective treatment regimen for this ulcer is required than the use of proton pump inhibitor (PPI) alone. Methodology: Patients with ESD-derived artificial ulcers were randomly assigned to two groups: a group of patients who received rabeprazole 20 mg daily for 8 weeks (PPI group) and a group of patients who received a combination of rebamipide 300 mg daily for 8 weeks and rabeprazole 20mg dairy for the first 4 weeks (reb+PPI group). The area reduction ratio and healing status of ulcers were evaluated endoscopically on postoperative 7, 28 and 56 days. Results: The overall ulcer area reduction ratio was higher in the reb+PPI group than in the PPI group, especially at an early stage. The ratio of progression to the H1 stage in the reb+PPI group was significantly higher than that in the PPI group, especially at an early stage. Conclusions: Treatment with 8 weeks of rebamipide plus the first 4 weeks of PPI demonstrated a reduction ratio of artificial ulcers superior to that with 8 weeks of PPI mono-therapy. This combination treatment is, therefore, one of the candidate treatment strategies against ESD-derived artificial ulcers.
AB - Background/Aims: Artificial ulcers remain a major complication after Endoscopic submucosal dissection (ESD). The development of more effective treatment regimen for this ulcer is required than the use of proton pump inhibitor (PPI) alone. Methodology: Patients with ESD-derived artificial ulcers were randomly assigned to two groups: a group of patients who received rabeprazole 20 mg daily for 8 weeks (PPI group) and a group of patients who received a combination of rebamipide 300 mg daily for 8 weeks and rabeprazole 20mg dairy for the first 4 weeks (reb+PPI group). The area reduction ratio and healing status of ulcers were evaluated endoscopically on postoperative 7, 28 and 56 days. Results: The overall ulcer area reduction ratio was higher in the reb+PPI group than in the PPI group, especially at an early stage. The ratio of progression to the H1 stage in the reb+PPI group was significantly higher than that in the PPI group, especially at an early stage. Conclusions: Treatment with 8 weeks of rebamipide plus the first 4 weeks of PPI demonstrated a reduction ratio of artificial ulcers superior to that with 8 weeks of PPI mono-therapy. This combination treatment is, therefore, one of the candidate treatment strategies against ESD-derived artificial ulcers.
UR - http://www.scopus.com/inward/record.url?scp=84928543588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928543588&partnerID=8YFLogxK
U2 - 10.5754/hge13631
DO - 10.5754/hge13631
M3 - Article
C2 - 25911899
AN - SCOPUS:84928543588
VL - 62
SP - 219
EP - 224
JO - Acta hepato-splenologica
JF - Acta hepato-splenologica
SN - 0172-6390
IS - 137
ER -